PT  - JOURNAL ARTICLE
AU  - Terebuh, Pauline
AU  - Olaker, Veronica R.
AU  - Kendall, Ellen K.
AU  - Kaelber, David C.
AU  - Xu, Rong
AU  - Davis, Pamela B.
TI  - Liver abnormalities following SARS-CoV-2 infection in children under 10 years of age
AID  - 10.1101/2023.09.21.23295905
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.21.23295905
4099  - http://medrxiv.org/content/early/2023/09/23/2023.09.21.23295905.short
4100  - http://medrxiv.org/content/early/2023/09/23/2023.09.21.23295905.full
AB  - Objective Beginning in October 2021 in the US and elsewhere, cases of severe pediatric hepatitis of unknown etiology were identified in young children. While the adenovirus and adenovirus-associated virus have emerged as leading etiologic suspects, we attempted to investigate a potential role for SARS-CoV-2 in the development of subsequent liver abnormalities.Design We conducted a study utilizing retrospective cohorts of de-identified, aggregated data from the electronic health records of over 100 million patients contributed by US health care organizations.Results Compared to propensity-score-matched children with other respiratory infections, children aged 1-10 years with COVID-19 had a higher risk of elevated transaminases (Hazard ratio (HR) (95% Confidence interval (CI)) 2.16 (1.74-2.69)) or total bilirubin (HR (CI) 3.02 (1.91-4.78)), or new diagnoses of liver diseases (HR (CI) 1.67 (1.21-2.30)) from one to six months after infection. Patients with pre-existing liver abnormalities, liver abnormalities surrounding acute infection, younger age (1-4 years), or illness requiring hospitalization all had similarly elevated risk. Children who developed liver abnormalities following COVID-19 had more pre-existing conditions than those who developed abnormalities following other infections.Conclusion These results indicate that SARS-CoV-2 may prime the patient for subsequent development of liver infections or non-infectious liver diseases. While rare (∼1 in 1,000), SARS-CoV-2 is a risk for subsequent abnormalities in liver function or the diagnosis of diseases of the liver.What is already known on this topic Clusters of severe hepatitis in children in 2022 coincident with the increase in COVID-19 infections in children raised the question of the contribution of SARS-CoV-2 to the hepatitis outbreak, though it was soon determined that SARS-CoV-2 was not the primary etiologic agent.What this study adds SARS-CoV-2 may prime the patient for subsequent development of liver infections or non-infectious liver diseases.How this study might affect research, practice or policy Despite the mild initial disease in children, there may be longer term consequences of COVID-19, such as liver abnormalities, that warrants further investigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the National Institutes of Health AG057557, AG061388, AG062272, AG076649 (all to RX), AA029831 and AG076649 to RX and PBD, and grant 1UL1TR002548-01 to Michael Konstan, which provided core infrastructure support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MetroHealth Institutional Review Board has designated this study as exempt.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript